Mandley
David John Mandley, Leeds GB
Patent application number | Description | Published |
---|---|---|
20110027335 | COATED MEDICAL DEVICES - An implantable medical device carries on at least part of its external surface a coating. The coating consists essentially of a terpolymer of vinyl pyrrolidone, acrylic acid and activated acrylic acid, and optionally a colouring agent. | 02-03-2011 |
David John Mandley, Yorkshire GB
Patent application number | Description | Published |
---|---|---|
20090018575 | TISSUE-ADHESIVE FORMULATIONS - A tissue-adhesive formulation comprises a particulate material having tissue-reactive functional groups, in admixture with a particulate buffer material. The formulation is preferably free or substantially free of materials of human or animal origin. In preferred embodiments, the formulation consists, or consists essentially of, an anhydrous or partially hydrated blend of particulate material having tissue-reactive functional groups and particulate buffer material. Also disclosed is a multilayer sheet comprising a structural support coated on at least one side thereof with such a tissue-adhesive formulation. | 01-15-2009 |
20090044895 | TISSUE-ADHESIVE MATERIALS - A multi-lamellar tissue-adhesive sheet comprises a structural layer or laminate conjoined to a tissue-contacting layer. The structural layer or laminate comprises one or more synthetic polymers having film-forming properties, and the tissue-contacting layer of material contains tissue-reactive groups. The synthetic polymers having film-forming properties are preferably biodegradable polyesters, and the tissue-reactive groups are most preferably NHS-ester groups. | 02-19-2009 |
Everton Mandley, Dorchester, MA US
Patent application number | Description | Published |
---|---|---|
20100099116 | Methods for Analysis of Hedgehog Pathway Inhibitors - One aspect of the present invention relates to a method of ascertaining the inhibitory activity in a mammal of a candidate inhibitor of the hedgehog pathway. In certain embodiments, the candidate inhibitor is administered systemically. In certain embodiments, the mammal is a rodent or primate. In certain embodiments, the mammal is a mouse. In certain embodiments, the candidate inhibitor is a small molecule or natural product. | 04-22-2010 |